-
Real-world Outcomes in Multiple Myeloma
Study shines a light on the differences in outcomes between clinical trial patients with multiple myeloma and those receiving cancer treatment in their community.
by Sandra Gordon
-
January 26: The Week in Cancer News
Questions about screening for women with dense breast tissue, and the FDA asks drugmakers to add a warning to labels for CAR T-cell therapies.
by Thomas Celona
-
Some Breast Cancer Patients May Safely Skip Radiation
Three presentations at SABCS in December find that it may be safe in certain cases for people with breast cancer to go without radiation.
by Cancer Research Catalyst
-
January 19: The Week in Cancer News
Preventive gastrectomy has lasting effects, and rising cancer incidence undercuts continued progress against mortality.
by Eric Fitzsimmons
-
January 12: The Week in Cancer News
Hiding serious illness can be a coping strategy, and cancer rates are on the rise among young people.
by Kevin McLaughlin
-
Doctors Urge Need for ‘Common Sense Oncology’
A movement of health care professionals say the toll of many cancer treatments is out of sync with the purported benefits.
by Kyle Bagenstose
-
January 5: The Week in Cancer News
The FDA will review a blood test that detects colon cancer, and a writer recounts his sister’s decision to receive medical aid in dying.
by Marci A. Landsmann
Cancer Talk
Screening Options for People With Dense Breasts
Reports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore
Designing Clinical Trials for the PatientChallenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon